by Plus Therapeutics | Jan 15, 2025 | Uncategorized
Stay Updated with Plus Therapeutics – Follow Us & Subscribe! Want the latest updates on Plus Therapeutics and cutting-edge industry news? Stay informed by following us on all our social media accounts and subscribing to our email newsletter! 🔹 Be the first to know...
by Plus Therapeutics | Jan 14, 2025 | GBM
ReSPECT-GBM Clinical Trial Update: Phase 2 Enrollment Now Open We are excited to announce that enrollment for the Phase 1 ReSPECT-GBM clinical trial is complete! We are actively enrolling patients for Phase 2 of the trial, which focuses on treating recurrent...
by Plus Therapeutics | Jan 10, 2025 | LM
Did You Know? Leptomeningeal Metastases (LM) Rise From Various Cancers Leptomeningeal metastases (LM) is a serious condition where cancer cells spread to the leptomeninges, the membranes that cover the brain and spinal cord. While any cancer can metastasize to the...
by Plus Therapeutics | Jan 7, 2025 | LM
🚀 Plus Therapeutics Doubles ReSPECT-LM Clinical Trial Locations in 2024 Plus Therapeutics is proud to announce that we have doubled the number of locations for our ReSPECT-LM clinical trial in 2024, expanding to 6 investigation sites nationwide. This significant...
by Plus Therapeutics | Jan 2, 2025 | Uncategorized
🎉 Happy New Year from Plus Therapeutics! 🎉 As we ring in the new year, we want to extend our heartfelt gratitude to the patients, medical staff, and the entire cancer community who have supported our mission throughout 2024. Thanks to your dedication and hard work,...
Recent Comments